SCHEMBL2178971

SCHEMBL2178971

CNc1nccc(-c2cc(NC(=O)c3ccccc3)c3cc(OC)ccc3c2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 3/20 0.48
HDAC3 O15379 1/20 0.48
NCOR1 O75376 1/20 0.48
PRKCA P17252 3/20 0.47
AURKB Q96GD4 2/20 0.45
AURKA O14965 1/20 0.45
TTK P33981 1/20 0.45
INCENP Q9NQS7 1/20 0.45
ADORA3 P0DMS8 3/20 0.45
SRC P12931 2/20 0.44
FLT3 P36888 1/20 0.44
ITK Q08881 1/20 0.44
MAPT P10636 3/20 0.43
KDM4E B2RXH2 1/20 0.43
HDAC1 Q13547 1/20 0.43
PIK3CA P42336 1/20 0.43
ABL1 P00519 2/20 0.43
PDGFRB P09619 2/20 0.43
BCR P11274 2/20 0.43
PDGFRA P16234 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175891 0.94 HDAC3 (0.49) HDAC2HDAC3NCOR1ADORA3SRC
SCHEMBL2178371 0.90 BTK (0.46) HDAC2HDAC3NCOR1SRCFLT3
SCHEMBL2175910 0.89 TDO2 (0.46) HDAC2HDAC3NCOR1AURKBAURKA
SCHEMBL2178148 0.87 HSD17B1 (0.46) HDAC2HDAC3NCOR1PIK3CASMN1; SMN2
SCHEMBL6128802 0.85 HDAC3 (0.43) HDAC2HDAC3NCOR1AURKBAURKA
SCHEMBL2178808 0.84 CASP2 (0.41) HDAC2HDAC3NCOR1PIK3CAPDGFRA
SCHEMBL6128772 0.84 NPC1 (0.44) HDAC2HDAC3NCOR1ADORA3PIK3CA
SCHEMBL2178751 0.83 AAK1 (0.42) HDAC2HDAC3NCOR1AURKBAURKA
SCHEMBL2176307 0.82 KDR (0.41) HDAC2HDAC3NCOR1PIK3CAABL1
SCHEMBL5465449 0.81 PIK3CA (0.58) HDAC2HDAC3NCOR1PRKCAADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US claimed
EP-2519519-A2 SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS ArQule, Inc. (US) 2012-11-07 EP disclosed
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US disclosed
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US disclosed
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds ARQULE, INC. (US) 2011-07-07 US disclosed
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds ARQULE, INC. (US) 2011-07-07 US disclosed
WO-2011082268-A2 SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS ARQULE INC. (US) 2011-07-07 WO disclosed
WO-2011082268-A2 SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS ARQULE INC. (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds DPYD, TP53, TYMP HDAC2 2152/4885HDAC3 1641/4885NCOR1 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.